Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.
